Can iron chelation as an adjunct treatment of COVID-19 improve the clinical outcome?

Saved in:

Bibliographic Details
Published in:	European journal of clinical pharmacology Vol. 76; no. 11; pp. 1619 - 1620
Main Author:	Abobaker, Anis
Format:	Journal Article
Language:	English
Published:	Berlin/Heidelberg Springer Berlin Heidelberg 01-11-2020
Subjects:	Animals Anti-Inflammatory Agents - pharmacology Anti-Inflammatory Agents - therapeutic use Antibodies, Neutralizing - blood Antiviral Agents - pharmacology B-Lymphocytes - drug effects B-Lymphocytes - immunology Betacoronavirus Biomedical and Life Sciences Biomedicine Coronavirus Infections - drug therapy COVID-19 Deferoxamine - pharmacology Deferoxamine - therapeutic use Enterovirus Infections - blood Enterovirus Infections - drug therapy Enterovirus Infections - immunology HIV-1 - drug effects HIV-1 - physiology Humans Immunologic Factors - pharmacology Immunologic Factors - therapeutic use Interleukin-6 - immunology Iron Chelating Agents - pharmacology Iron Chelating Agents - therapeutic use Iron Overload - drug therapy Letter to the Editor Mice Pandemics Pharmacology/Toxicology Pneumonia, Viral - drug therapy SARS-CoV-2 Treatment Outcome Virus Replication - drug effects
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Bibliography:	SourceType-Other Sources-1 content type line 63 ObjectType-Correspondence-1
ISSN:	0031-6970 1432-1041
DOI:	10.1007/s00228-020-02942-9